MedTrace Logo

Metformin-Dipyridamole Interaction Trial

NCT01613755 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-04-29

No results posted yet for this study

Summary

The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. It has recently been suggested that the gastrointestinal absorption of metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has been reported to inhibit hENT4 transport in vitro. The aim of this research proposal is to study the pharmacokinetic interaction between metformin and dipyridamole. The investigators hypothesize that dipyridamole reduces the gastrointestinal absorption of metformin. If this hypothesis can be confirmed, then the results of this study can explain in part the high variability in plasma metformin concentrations in patients treated with diabetes, and can be used to optimize pharmacotherapy in patients with diabetes.

Conditions

Interventions

DRUG

Metformin, dipyridamole

Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days

DRUG

Metformin

Metformin 500 mg twice daily for four days

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • N. Riksen, MD, PhD · Radboud University Medical Center

  • G. Rongen, MD, PhD · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613755 on ClinicalTrials.gov